05/26/22 7:30 AMNasdaq : KURA conferencesKura Oncology to Participate in Three Upcoming Investor ConferencesKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,RHEA-AIneutral
05/04/22 4:05 PMNasdaq : KURA earningsKura Oncology Reports First Quarter 2022 Financial Results– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohortRHEA-AIneutral
04/27/22 7:30 AMNasdaq : KURA conferencesearningsKura Oncology to Report First Quarter 2022 Financial ResultsKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after theRHEA-AIneutral
04/08/22 1:00 PMNasdaq : KURA clinical trialKura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combination with osimertinib in NSCLC in the thirdRHEA-AIneutral
03/08/22 5:30 PMNasdaq : KURA Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual MeetingKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for theRHEA-AIneutral
02/28/22 7:30 AMNasdaq : KURA conferencesKura Oncology to Participate in Two Upcoming Investor ConferencesKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,RHEA-AIneutral
02/24/22 4:03 PMNasdaq : KURA earningsKura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC – – Abstract supporting next-generation FTI programRHEA-AIneutral
02/17/22 7:30 AMNasdaq : KURA conferencesearningsKura Oncology to Report Fourth Quarter and Full Year 2021 Financial ResultsKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financialRHEA-AIneutral
02/10/22 7:30 AMNasdaq : KURA conferencesKura Oncology to Participate in SVB Leerink Global Healthcare ConferenceKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11 th Annual SVB Leerink Global HealthcareRHEA-AIneutral
02/01/22 4:01 PMNasdaq : KURA managementKura Oncology Expands Leadership Team with Key PromotionsKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, todayRHEA-AIvery positive